How many institutions held NMRA - Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value in Q2 2025?

96 institutional investors reported NMRA - Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value for Q2 2025. Use the holders table for investor-level position and value details.

Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value (NMRA)

Q: What does CUSIP 640979100 represent in this 13F holders report?

CUSIP 640979100 is the security identifier for NMRA - Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value used to aggregate holder disclosures.

CUSIP: 640979100

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, $0.0001 par value
Shares outstanding: 181,633,257
Total 13F shares: 56,105,109
Share change: -8,302,432
Total reported value: $41,177,547
Put/Call ratio: 54%
Price per share: $0.73
Number of holders: 96
Value change: -$6,520,439
Number of buys: 51
Number of sells: 66

Quarterly Holders Quick Answers

What is CUSIP 640979100?
CUSIP 640979100 identifies NMRA - Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 640979100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of NMRA - Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
AMGEN INC	3/4/5	10%+ Owner	— class O/S missing	35,368,653	$423,716,463	—	19 Sep 2023	3/4/5
FMR LLC	3/4/5 13D/G 13F	Other* · Company	2.2% from 13D/G	5,624,353	$67,379,749	—	19 Sep 2023	3/4/5 13D/G 13F
Gosebruch Henry O	3/4/5	President & CEO, Director	— mixed-class rows	749,793 mixed-class rows	$7,065,720	—	14 Feb 2024	3/4/5
SOFTBANK GROUP CORP.	13F	Company	3.6%	6,541,190	$6,541,190	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	3.5%	6,354,533	$6,354,533	—	31 Mar 2025	13F
Paul L. Berns	13D/G	—	5.1%	8,226,272	$6,334,229	$0	31 Dec 2024	13D/G
VANGUARD GROUP INC	13F	Company	2.9%	5,325,037	$5,325,037	—	31 Mar 2025	13F
Carol Y. Suh	3/4/5	Chief Operating Officer	— mixed-class rows	544,674 mixed-class rows	$4,488,595	—	14 Feb 2024	3/4/5
MIC Capital Management UK LLP	13F	Company	2.5%	4,460,700	$4,460,700	—	31 Mar 2025	13F
Siren, L.L.C.	13F	Individual	2.4%	4,358,283	$4,358,283	—	31 Mar 2025	13F
WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST	13F	Company	1.8%	3,309,123	$3,309,123	—	31 Mar 2025	13F
UBS Group AG	13F	Company	1.7%	3,106,556	$3,106,556	—	31 Mar 2025	13F
ICONIQ Capital, LLC	13F	Company	1.4%	2,559,090	$2,559,090	—	31 Mar 2025	13F
Lunate Capital Ltd	13F	Company	1.2%	2,124,143	$2,124,143	—	31 Mar 2025	13F
T. Rowe Price Investment Management, Inc.	13F	Company	1.2%	2,103,029	$2,104,000	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.1%	1,976,302	$1,976,797	—	31 Mar 2025	13F
JOHNSON & JOHNSON	13F	Company	1%	1,849,445	$1,849,445	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.95%	1,721,804	$1,721,804	—	31 Mar 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	0.77%	1,400,000	$1,400,000	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.69%	1,259,530	$1,259,530	—	31 Mar 2025	13F
Graham Capital Management, L.P.	13F	Company	0.64%	1,162,499	$1,162,499	—	31 Mar 2025	13F
BAKER BROS. ADVISORS LP	13F	Company	0.57%	1,034,600	$1,034,600	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.48%	869,022	$869,022	—	31 Mar 2025	13F
MORGAN STANLEY	13F	Company	0.47%	852,372	$852,372	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.4%	718,326	$718,326	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.38%	689,251	$689,251	—	31 Mar 2025	13F
Callan Capital, LLC	13F	Company	0.35%	638,784	$638,784	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.33%	607,784	$607,784	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.33%	593,498	$593,498	—	31 Mar 2025	13F
Robert A. Lenz	3/4/5	Head of R&D	— mixed-class rows	409,092 mixed-class rows	$516,616	—	18 Feb 2025	3/4/5
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.25%	462,603	$462,603	—	31 Mar 2025	13F
Matthew K. Fust	3/4/5	Director	— mixed-class rows	100,100 mixed-class rows	$342,395	—	28 May 2025	3/4/5
Cerity Partners LLC	13F	Company	0.17%	302,505	$302,505	—	31 Mar 2025	13F
FEDERATED HERMES, INC.	13F	Company	0.16%	284,576	$284,576	—	31 Mar 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.15%	274,314	$274,314	—	31 Mar 2025	13F
Verition Fund Management LLC	13F	Company	0.15%	271,363	$271,363	—	31 Mar 2025	13F
Alaa Halawa	3/4/5	Director	— mixed-class rows	100,100 mixed-class rows	$240,798	—	28 May 2025	3/4/5
David Piacquad	3/4/5	Director	— mixed-class rows	100,100 mixed-class rows	$240,798	—	28 May 2025	3/4/5
Maykin Ho	3/4/5	Director	— mixed-class rows	100,100 mixed-class rows	$240,798	—	28 May 2025	3/4/5
XTX Topco Ltd	13F	Company	0.13%	233,597	$233,597	—	31 Mar 2025	13F
Bank of New York Mellon Corp	13F	Company	0.13%	227,855	$227,855	—	31 Mar 2025	13F
Nuveen, LLC	13F	Company	0.12%	220,970	$220,970	—	31 Mar 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.11%	197,030	$197,030	—	31 Mar 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0.1%	190,588	$190,588	—	31 Mar 2025	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.1%	188,418	$188,418	—	31 Mar 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.1%	186,713	$187,000	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.1%	182,341	$182,341	—	31 Mar 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.1%	176,200	$176,200	—	31 Mar 2025	13F
Addis & Hill, Inc	13F	Company	0.09%	163,386	$163,386	—	31 Mar 2025	13F
Squarepoint Ops LLC	13F	Company	0.07%	127,995	$127,995	—	31 Mar 2025	13F

Institutional Holders of Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value (NMRA) as of Q2 2025

As of 30 Jun 2025, Neumora Therapeutics, Inc. - Common Stock, $0.0001 par value (NMRA) was held by 96 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 56,105,109 shares. The largest 10 holders included SOFTBANK GROUP CORP., VANGUARD GROUP INC, MIC Capital Management UK LLP, Siren, L.L.C., FMR LLC, WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST, BlackRock, Inc., ICONIQ Capital, LLC, Lunate Capital Ltd, and T. Rowe Price Investment Management, Inc.. This page lists 95 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

111

Q2 2025 holders

Holder diff

-15

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.